HAYA To Complement Lilly’s Metabolic Disease Efforts With Long Non-Coding RNA

 
• By Joseph Haas

HAYA, a pioneer in lncRNA, is teaming up with Lilly to discover novel targets and programmable RNA therapies for obesity and metabolic disorders.

Dark genome
HAYA is partnering with Lilly on dark genome-derived therapies • Source: Shutterstock

More from Deals

More from Business